Laboratory of Hepatobiliary and Pancreatic Surgery, the Affiliated Hospital of Guilin Medical University, Guilin, 541001, Guangxi, People's Republic of China.
China-USA Lipids in Health and Disease Research Center, Guilin Medical University, Guilin, 541001, Guangxi, People's Republic of China.
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2020 Jun;164(2):203-208. doi: 10.5507/bp.2019.015. Epub 2019 Apr 17.
The roles of sphingosine in various cancers have not been fully investigated. Our aim was to identify the relationship between serum sphingosine and the risk of hepatocellular carcinoma (HCC).
Serum sphingosine in 34 normal people and 73 HCC patients were reviewed retrospectively. Receiver operating characteristic curve analysis was performed to determine the cut-off values of sphingosine in the serum. Chi-square test, t test and regression analysis were used to test the association between serum sphingosine and individual clinicopathologic parameters.
Serum sphingosine was higher in HCC patients (155.91±331.5 ng/mL) with normal persons as the control (30.92±29.4 ng/mL). The sphingosine threshold according to ROC curve was set at 22.5 ng/mL with a sensitivity of 74%, and a specificity of 55.9%. Meanwhile, sphingosine in HCC patients with abnormal albumin was significantly higher than that in patients with normal albumin (t=2.452, P=0.019). When HCC patients were divided into two groups serum sphingosine was negatively associated with albumin in HCC patients (χ=4.469, P=0.035). Moreover, the logistic regression analysis showed that large tumor size (P=0.018, OR=0.13) and a low albumin (P=0.005, OR=8.856) were two independent risk factors for serum sphingosine upregulation. High AFP coupled with high serum sphingosine, high sphingosine and high AFP respectively were found in 91.2%, 75.4%, 73% of the HCC patients.
These results suggest that serum sphingosine could be treated as a marker for the risk of HCC. AFP and sphingosine in the serum could be used together for HCC diagnosis.
神经醇在各种癌症中的作用尚未被充分研究。我们的目的是确定血清神经醇与肝细胞癌（HCC）风险之间的关系。
回顾性分析 34 名正常人及 73 名 HCC 患者的血清神经醇水平。通过受试者工作特征曲线分析确定血清神经醇的截断值。采用卡方检验、t 检验和回归分析来检验血清神经醇与个体临床病理参数之间的相关性。
与正常对照组（30.92±29.4ng/mL）相比，HCC 患者的血清神经醇水平更高（155.91±331.5ng/mL）。根据 ROC 曲线确定的神经醇阈值为 22.5ng/mL，其敏感性为 74%，特异性为 55.9%。同时，白蛋白异常的 HCC 患者的神经醇明显高于白蛋白正常的患者（t=2.452，P=0.019）。当将 HCC 患者分为两组时，血清神经醇与 HCC 患者的白蛋白呈负相关（χ=4.469，P=0.035）。此外，逻辑回归分析显示，肿瘤较大（P=0.018，OR=0.13）和白蛋白较低（P=0.005，OR=8.856）是血清神经醇上调的两个独立危险因素。在 HCC 患者中，高 AFP 联合高血清神经醇、高神经醇联合高 AFP 及高 AFP 分别为 91.2%、75.4%和 73%。
这些结果表明，血清神经醇可作为 HCC 风险的标志物。血清 AFP 和神经醇可联合用于 HCC 的诊断。
